Successful Translation and Linguistic Validation of COAs: the Impact of Language Selections for Modern Chinese Populations
As the scale and frequency of clinical trials conducted in the Asia-Pacific region has increased, pharmaceutical and life sciences companies have encountered challenges in selecting the appropriate written variants of Chinese in a variety of countries. Selecting the appropriate variant is particularly important when translating and linguistically validating Clinical Outcomes Assessments (COAs) and Patient Reported Outcomes (PROs), which are used to directly collect patient data.
To help provide clarity, the RWS Life Sciences Linguistic Validation team analyzed the written and spoken variants of Chinese and their applicability across countries and regions. By providing a detailed discussion of both the history and current usage of each variant, we can recommend best practices by country.